La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Orgenesis a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Orgenesis..

Orgenesis (OTC:ORGS) Azioni, Catena delle Opzioni

Orgenesis

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Orgenesis Inc

Orgenesis (ORGS) just unveiled an announcement. During Orgenesis Inc.'s 2024 annual stockholders' meeting, a key amendment was approved to increase...

Orgenesis Annual Meeting: Board Changes and Share Increase

Orgenesis (ORGS) just unveiled an announcement. Curtis Slipman resigned from his director position at Orgenesis Inc. for personal reasons, not due ...

Orgenesis Announces Board Reshuffle and New Audit Member

Orgenesis GAAP EPS of $0.23

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Orgenesis</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/orgs-stock-quote/"><strong>ORGS</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Orgenesis reported earnings per share of -23 cents.</li><li>The company reported revenue of $246,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/orgs-stock-earnings-orgenesis-for-q2-of-2024/">ORGS Stock Earnings: Orgenesis Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ORGS Stock Earnings: Orgenesis Reported Results for Q2 2024

Orgenesis (ORGS) just unveiled an announcement. Orgenesis Inc. has prepared a presentation for potential investors and other interested parties, wh...

Orgenesis Releases Investor Presentation and Regulatory Update

Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance

Orgenesis ( ($ORGS) ) has shared an announcement. Orgenesis Inc. has announced a 1-for-10 reverse stock split effective September 24, 2024, to elev...

Orgenesis Announces Reverse Stock Split to Maintain Nasdaq Compliance

Orgenesis (ORGS) announced that its common stock will begin trading on the OTCQX Best Market under the ticker symbol "ORGS" following its delisting...

Orgenesis commences trading on OTCQX Best Market

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Orgenesis ( ($ORGS) ) has provided an update. The Company's Board of Directors has expanded from four to seven members with the addition of Adam Pe...

Orgenesis Expands Board with Three New Appointments

CYCC

FOLD

ORGS

TEVA

Press Releases

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

News

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Comments

Orgenesis

Orgenesis (ORGS) Opzioni

Orgenesis (OTC:ORGS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO